Neuralstem Company Profile (NASDAQ:CUR)

About Neuralstem (NASDAQ:CUR)

Neuralstem logoNeuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CUR
  • CUSIP: N/A
  • Web: www.neuralstem.com
Capitalization:
  • Market Cap: $52.36 million
  • Outstanding Shares: 11,899,000
Average Prices:
  • 50 Day Moving Avg: $4.60
  • 200 Day Moving Avg: $3.12
  • 52 Week Range: $2.47 - $6.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16,246.00
  • Price / Sales: 3,222.68
  • Book Value: $0.83 per share
  • Price / Book: 5.30
Profitability:
  • EBIDTA: ($18,210,000.00)
  • Net Margins: -170,366.66%
  • Return on Equity: -4,420.33%
  • Return on Assets: -174.10%
Debt:
  • Current Ratio: 0.85%
  • Quick Ratio: 0.85%
Misc:
  • Average Volume: 141,035 shs.
  • Beta: 1.63
  • Short Ratio: 2.1
 

Frequently Asked Questions for Neuralstem (NASDAQ:CUR)

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) posted its earnings results on Tuesday, November, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. Neuralstem had a negative net margin of 170,366.66% and a negative return on equity of 4,420.33%. View Neuralstem's Earnings History.

Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2017?

3 brokers have issued 1-year price objectives for Neuralstem's shares. Their forecasts range from $1.20 to $4.00. On average, they anticipate Neuralstem's stock price to reach $2.79 in the next year. View Analyst Ratings for Neuralstem.

Who are some of Neuralstem's key competitors?

Who owns Neuralstem stock?

Neuralstem's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.09%), Alethea Capital Management LLC (1.49%), Geode Capital Management LLC (0.72%), KCG Holdings Inc. (0.62%), Blair William & Co. IL (0.29%) and National Asset Management Inc. (0.18%). Company insiders that own Neuralstem stock include Jones Jonathan Brian Lloyd, Karl Johe and Richard J Daly. View Institutional Ownership Trends for Neuralstem.

Who sold Neuralstem stock? Who is selling Neuralstem stock?

Neuralstem's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC, Blair William & Co. IL, National Asset Management Inc. and KCG Holdings Inc.. View Insider Buying and Selling for Neuralstem.

Who bought Neuralstem stock? Who is buying Neuralstem stock?

Neuralstem's stock was bought by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC. Company insiders that have bought Neuralstem stock in the last two years include Jones Jonathan Brian Lloyd and Richard J Daly. View Insider Buying and Selling for Neuralstem.

How do I buy Neuralstem stock?

Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Neuralstem stock cost?

One share of Neuralstem stock can currently be purchased for approximately $4.40.

Analyst Ratings

Consensus Ratings for Neuralstem (NASDAQ:CUR) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.79 (36.52% downside)

Analysts' Ratings History for Neuralstem (NASDAQ:CUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/16/2017S&P Equity ResearchLower Price Target$3.69 -> $3.18N/AView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$1.20N/AView Rating Details
11/7/2016AegisInitiated CoverageBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$4.00N/AView Rating Details
6/30/2015MLV & Co.Initiated CoverageBuyN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Neuralstem (NASDAQ:CUR)
Earnings by Quarter for Neuralstem (NASDAQ:CUR)
Earnings History by Quarter for Neuralstem (NASDAQ:CUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016Q3($0.03)($0.05)ViewN/AView Earnings Details
8/11/2016Q2($0.05)($0.04)$2.50 million$2.50 millionViewN/AView Earnings Details
5/9/2016Q1($0.06)($0.07)ViewN/AView Earnings Details
3/14/2016Q4($0.07)($0.05)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q2($0.06)($0.06)ViewN/AView Earnings Details
5/8/2015Q115($0.07)($0.06)$2.92 millionViewN/AView Earnings Details
4/20/2015($0.07)($0.06)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.05)($0.06)$0.01 millionViewN/AView Earnings Details
11/7/2014Q314($0.05)($0.05)$0.01 millionViewN/AView Earnings Details
8/8/2014Q214($0.05)($0.08)$0.10 million$0.01 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.04)$0.35 million$0.00 millionViewN/AView Earnings Details
3/10/2014Q4 2013($0.06)($0.04)ViewN/AView Earnings Details
11/11/2013Q3($0.04)($0.09)ViewN/AView Earnings Details
8/9/2013Q213($0.05)($0.09)$0.08 million$0.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.04)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neuralstem (NASDAQ:CUR)
Current Year EPS Consensus Estimate: $-2.26 EPS
Next Year EPS Consensus Estimate: $-2.24 EPS

Dividends

Dividend History for Neuralstem (NASDAQ:CUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neuralstem (NASDAQ:CUR)
Insider Ownership Percentage: 19.25%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Institutional Ownership by Quarter for Neuralstem (NASDAQ:CUR)
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Richard J DalyCEOBuy7,500$4.00$30,000.00View SEC Filing  
3/24/2017Jones Jonathan Brian LloydCFOBuy5,455$5.50$30,002.50View SEC Filing  
2/24/2017Richard J DalyCEOBuy2,591$3.86$10,001.26View SEC Filing  
1/25/2017Richard J DalyCEOBuy2,841$3.52$10,000.32View SEC Filing  
12/23/2016Richard J DalyCEOBuy32,259$0.31$10,000.29View SEC Filing  
11/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
10/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
9/23/2016Richard J DalyCEOBuy31,250$0.32$10,000.00View SEC Filing  
11/16/2015Karl JoheInsiderSell25,000$1.09$27,250.00View SEC Filing  
11/9/2015Karl JoheInsiderSell25,000$1.18$29,500.00View SEC Filing  
11/2/2015Karl JoheInsiderSell25,000$1.17$29,250.00View SEC Filing  
10/26/2015Karl JoheInsiderSell25,000$1.13$28,250.00View SEC Filing  
10/19/2015Karl JoheInsiderSell25,000$1.23$30,750.00View SEC Filing  
10/12/2015Karl JoheInsiderSell25,000$1.31$32,750.00View SEC Filing  
10/5/2015Karl JoheInsiderSell25,000$1.26$31,500.00View SEC Filing  
9/28/2015Karl JoheInsiderSell25,000$1.64$41,000.00View SEC Filing  
9/21/2015Karl JoheInsiderSell25,000$1.52$38,000.00View SEC Filing  
9/2/2014Karl JoheInsiderSell6,000$4.09$24,540.00View SEC Filing  
8/1/2014Karl JoheInsiderSell6,000$2.78$16,680.00View SEC Filing  
7/1/2014Karl JoheInsiderSell6,000$4.17$25,020.00View SEC Filing  
6/2/2014Karl JoheInsiderSell6,000$4.25$25,500.00View SEC Filing  
5/5/2014William Clyde OldakerDirectorBuy15,235$3.50$53,322.50View SEC Filing  
4/22/2014Richard GarrCEOSell7,000$4.25$29,750.00View SEC Filing  
4/1/2014Karl JoheInsiderSell6,000$4.11$24,660.00View SEC Filing  
3/20/2014Karl JoheInsiderSell6,000$4.04$24,240.00View SEC Filing  
10/18/2013Karl JoheInsiderSell10,000$2.44$24,400.00View SEC Filing  
9/20/2013Karl JoheInsiderSell10,000$2.62$26,200.00View SEC Filing  
9/19/2013Karl JoheInsiderSell10,000$2.61$26,100.00View SEC Filing  
8/20/2013Karl JoheInsiderSell20,000$1.55$31,000.00View SEC Filing  
7/22/2013Karl JoheInsiderSell12,800$1.62$20,736.00View SEC Filing  
6/20/2013Karl JoheInsiderSell12,800$1.40$17,920.00View SEC Filing  
6/7/2013Richard GarrCEOSell6,000$1.42$8,520.00View SEC Filing  
5/20/2013Karl JoheInsiderSell12,800$1.51$19,328.00View SEC Filing  
2/25/2013Richard GarrCEOSell12,000$1.15$13,800.00View SEC Filing  
11/20/2012Karl JoheInsiderSell12,800$1.00$12,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neuralstem (NASDAQ:CUR)
Latest Headlines for Neuralstem (NASDAQ:CUR)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:22 PM
americanbankingnews.com logoRichard J. Daly Buys 7,500 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - May 18 at 1:32 PM
streetinsider.com logoNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder
www.streetinsider.com - May 17 at 9:42 PM
streetinsider.com logoNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.com
www.streetinsider.com - May 17 at 4:41 PM
finance.yahoo.com logoNeuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
finance.yahoo.com - May 17 at 4:41 PM
finance.yahoo.com logoNeuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:08 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: MannKind and Neuralstem
finance.yahoo.com - May 11 at 5:14 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:14 PM
finanznachrichten.de logoGainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM...
www.finanznachrichten.de - May 11 at 2:49 AM
americanbankingnews.com logoZacks: Neuralstem, Inc. (CUR) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 10 at 8:44 PM
globenewswire.com logoNeuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
globenewswire.com - May 10 at 4:47 PM
finance.yahoo.com logoNeuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
finance.yahoo.com - May 10 at 4:47 PM
seekingalpha.com logoNeuralstem, Inc. (CUR)
seekingalpha.com - May 4 at 9:45 PM
americanbankingnews.com logoNeuralstem (CUR) Receiving Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 21 at 6:28 PM
businesswire.com logoBioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development
www.businesswire.com - April 20 at 4:45 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 4:34 PM
americanbankingnews.com logoNeuralstem (CUR) Getting Somewhat Negative Media Coverage, Report Finds
www.americanbankingnews.com - April 13 at 12:54 PM
streetinsider.com logoNeuralstem (CUR) Adds Four Cohorts to Ongoing Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury - StreetInsider.com
www.streetinsider.com - April 13 at 11:48 AM
finance.yahoo.com logoNeuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury
finance.yahoo.com - April 12 at 11:22 AM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:16 AM
americanbankingnews.com logoJones Jonathan Brian Lloyd Acquires 5,455 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - March 27 at 11:05 PM
biz.yahoo.com logoNEURALSTEM, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 23 at 5:09 PM
us.rd.yahoo.com logoNeuralstem Reports Year End 2016 Fiscal Results and Business Update
us.rd.yahoo.com - March 23 at 5:09 PM
streetinsider.com logoNeuralstem (CUR) Reports Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury - StreetInsider.com
www.streetinsider.com - March 11 at 10:09 AM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 11 at 12:43 AM
us.rd.yahoo.com logoToday's Research Reports on Market Movers: Neuralstem and Real Goods Solar
us.rd.yahoo.com - March 10 at 5:39 PM
us.rd.yahoo.com logoNeuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury
us.rd.yahoo.com - March 9 at 5:11 PM
globenewswire.com logoNeuralstem to Present at 29th Annual ROTH Conference - GlobeNewswire (press release)
www.globenewswire.com - March 8 at 10:20 PM
streetinsider.com logoNeuralstem (CUR) Announces Publication of NSI-189 Preclinical Data
www.streetinsider.com - March 1 at 1:18 PM
streetinsider.com logoNeuralstem (CUR) Announces Publication of NSI-189 Preclinical Data - StreetInsider.com
www.streetinsider.com - February 28 at 4:48 PM
us.rd.yahoo.com logoNeuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
us.rd.yahoo.com - February 28 at 10:33 AM
biz.yahoo.com logoNEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 27 at 5:47 PM
us.rd.yahoo.com logoNeuralstem Announces Issuance of U.S. Patent Covering NSI-189
us.rd.yahoo.com - February 22 at 4:49 PM
us.rd.yahoo.com logo7:04 am Neuralstem confirms that U.S. Patent No. 9572807 was issued by the United States Patent and Trademark Office for NSI-189 the lead compound in Neuralstem's neurogenic small molecule program in development for the treatment of major d
us.rd.yahoo.com - February 22 at 4:49 PM
streetinsider.com logoNeuralstem (CUR) Confirms US Patent Covering NSI-189 - StreetInsider.com
www.streetinsider.com - February 22 at 9:25 AM
streetinsider.com logoUPDATE: Neuralstem (CUR) Halted on LUDP After Announcing Phase 2 NSI-189 Data Now Expected Ahead of Schedule
www.streetinsider.com - February 16 at 6:39 PM
streetinsider.com logoUPDATE: Neuralstem (CUR) Halted on LUDP After Announcing Phase 2 NSI-189 Data Now Expected Ahead of Schedule
www.streetinsider.com - February 16 at 6:39 PM
biz.yahoo.com logoNEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 16 at 6:39 PM
feeds.benzinga.com logo18 Biggest Mid-Day Gainers For Thursday
feeds.benzinga.com - February 16 at 1:42 PM
benzinga.com logo18 Biggest Mid-Day Gainers For Thursday - Benzinga
www.benzinga.com - February 16 at 1:38 PM
streetinsider.com logoUPDATE: Neuralstem (CUR) Halted on LUDP After Announcing Phase 2 NSI-189 Data Now Expected Ahead of ... - StreetInsider.com
www.streetinsider.com - February 16 at 1:38 PM
finance.yahoo.com logoNeuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
finance.yahoo.com - February 16 at 1:38 PM
globenewswire.com logoNeuralstem to Present at BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 14 at 3:47 PM
finance.yahoo.com logoNeuralstem to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 13 at 5:16 PM

Social

Chart

Neuralstem (CUR) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff